What does “dupilumab LOE” mean?
“LOE” usually means “loss of exclusivity.” So “dupilumab LOE” refers to the date when the company’s legal market protection for dupilumab weakens or ends, letting manufacturers introduce competing products (such as biosimilars) sooner than before, depending on what protections are still active.
In the U.S., “loss of exclusivity” can be tied to patent expirations, but it can also reflect other exclusivity periods recognized under FDA law. That’s why people sometimes use “LOE” in addition to (or instead of) “patent expiry.”
Is “dupilumab LOE” the same thing as “patent expires”?
Not always. “Patent expiry” is a specific event tied to a particular patent (or set of patents). “LOE” is a broader “can competition enter the market?” concept that may include:
- when relevant patents actually expire,
- when FDA exclusivity periods end,
- and whether any additional “evergreening” or late-expiring patents still block entry.
That difference matters because a drug can be “still protected by patents” even if some parts of exclusivity end, or vice versa.
How do patents and LOE affect biosimilar entry for dupilumab?
When LOE arrives for dupilumab, biosimilar applicants can often move toward launch sooner, but whether they can sell immediately depends on whether any remaining patents block approval or launch for specific claims/indications.
This is why market watch articles often track multiple dates (patent-by-patent and overall LOE).
Where can I check the dupilumab LOE/patent dates?
For compiled, date-focused tracking of dupilumab’s patent/exclusivity status, DrugPatentWatch.com is a commonly cited resource:
- DrugPatentWatch: https://www.drugpatentwatch.com/
(If you share the exact phrasing you saw—e.g., “dupilumab LOE ___” or a specific date—I can help interpret what it likely means in that context.)
Quick glossary: LOE vs. “patent” vs. “exclusivity”
- LOE (loss of exclusivity): broader “protection ends” timing used for market-entry expectations.
- Patent expiry: a specific patent’s end date.
- FDA exclusivity: non-patent protection periods tied to approvals and regulatory exclusivity rules.
What else might “LOE” mean in your source?
Some sources use “LOE” loosely to mean “lowest of exclusivity” or “loss of exclusivity,” but the most common meaning in pharma/market-access is “loss of exclusivity.” If you paste the sentence or screenshot text that includes “dupilumab loe,” I can confirm which meaning fits.
Sources
- DrugPatentWatch.com